uk.investing.com on MSN30m
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bidHalozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback